Skip to content
Subscriber Only

Sanofi Said to Mull Sale of Bio-Surgery, Renal Businesses

  • Potential disposals considered as part of strategic review
  • Drugmaker is also weighing options for Merial animal health
Updated on

Drugmaker Sanofi is considering the disposal of its bio-surgery and renal units as part of a business review led by Chief Executive Officer Olivier Brandicourt, according to people familiar with the situation. Shares of the drugmaker jumped the most in a month.

Paris-based Sanofi, France’s biggest company by market value, is also considering options for its Merial animal health unit, three of the people said, asking not to be identified as the deliberations are private. No final decision has been made and Sanofi may choose to keep the assets, they said. An update on the process is expected at an investor meeting in November.